PHRecommendable#2 in categoryHIGH CONVICTIONSecondary Pick

Nippon India Pharma Fund

Nippon India MF · Sailesh Raj Bhan · benchmarked to Nifty Pharma TRI

Prospera Research Engine v7 · Data as of 24 Aug 2026 · Synced 14 Sept 2026Review date unknown — validation required

Prospera VerdictProspera Recommended

BEATS 3-10: Sailesh Raj Bhan 20Y pharma tenure unmatched. Sun Pharma + Divis + Abbott India = quality portfolio. PH-003 SBI (68) has higher ER (0.89%) and less experienced team. PH-005 ICICI Pru smaller AUM constraints.

Final Score77.0

1Y Return7.1%

3Y CAGR16.9%

5Y CAGR29.3%

AUM₹7.2K Cr

Expense Ratio0.72%

Eligibility: All gates passed

Prospera Research

Score Breakdown

13 weighted parameters, exactly as configured in the Research Engine — 8 qualitative (analyst-scored) plus 5 quantitative (formula-derived), summing to a final score out of 100.

Momentum (7% weight)7.0/10

3–6M price+flow vs benchmark

Consistency (10% weight)9.0/10

3Y/5Y quartile rank stability

Portfolio Quality (11% weight)8.0/10

PE, concentration, churn

Fund Mgr Quality (12% weight)9.0/10

Philosophy, communication, style drift

Valuation Risk (10% weight)6.0/10

Portfolio PE/PB vs category avg

Sector Tailwinds (9% weight)7.0/10

Policy/macro drivers 12-18M

Downside Protection (8% weight)8.0/10

Max DD, Sortino, bear markets

Outperformance Prob. (8% weight)7.0/10

Analyst 12M alpha probability

Mgr Tenure Score (8% weight)10.0/10

Years managing fund → 1-10 score

AMC Quality Score (6% weight)8.0/10

Research depth, AUM scale, compliance

AUM Trend Score (5% weight)6.0/10

Growing=9, Stable=6, Declining=3

Expense Ratio Score (4% weight)5.0/10

Inverse ER — lower cost = higher score

Thesis Strength (2% weight)7.0/10

Analyst 12-24M thesis conviction

Final Score77.0/100

Prospera Research

Why This Fund

Stance: 12% max allocation

Prospera Research

Analyst Write-Up

A full analyst write-up hasn't been published for this fund yet — only shortlisted funds at the review stage get one. The score breakdown and performance data above are still real and current.

Prospera Research

Risk-Adjusted Performance

3Y Alpha—

5Y Alpha-2.9%

Max Drawdown29.3%

Sharpe (3Y)0.84

Sortino (3Y)1.08

Beta0.76

Alpha Consistency82%

Prospera Research

AMC & Manager Intelligence

Nippon India MF

AA+ — TIER 1

28-analyst research team · Clean — 0 violations

Strong research bench especially in mid and small cap. Rupesh Patel and Samir Rachh represent the deepest domain expertise in their respective categories. Japanese parent provides governance stability.

Sailesh Raj Bhan

EXCEPTIONAL

20Y tenure · Sector Specialist · Confidence 9/10

20Y pharma-focused tenure — the longest sector specialist tenure in Indian MF history. Has navigated 4 USFDA cycles, 3 pricing crises, and 2 patent cliff periods. Irreplaceable sector knowledge.